Prosecution Insights
Last updated: July 17, 2026
Application No. 18/320,929

COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS

Final Rejection §102§112
Filed
May 19, 2023
Priority
Nov 03, 2017 — provisional 62/581,149 +2 more
Examiner
HAVLIN, ROBERT H
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Université de Montréal
OA Round
2 (Final)
52%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
535 granted / 1033 resolved
-8.2% vs TC avg
Strong +28% interview lift
Without
With
+27.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
83 currently pending
Career history
1134
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
37.5%
-2.5% vs TC avg
§102
14.2%
-25.8% vs TC avg
§112
32.0%
-8.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1033 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a DIV of 16/760,780 (04/30/2020, US11696928) 16/760,780 is a 371 of PCT/IB2018/058593 (11/01/2018) PCT/IB2018/058593 has PRO 62/581,149 (11/03/2017). Election/Restrictions Applicant's election of species without traverse of the following in the reply filed on 12/5/2025 is acknowledged. PNG media_image1.png 134 520 media_image1.png Greyscale The elected species corresponds to claim 1 formula I: PNG media_image2.png 169 384 media_image2.png Greyscale when V1 is N; V2 is CH; W is C; X is S; R1 is CH3; R2 is H; R3 is 4-chlorophenyl; and is determined to read on claims 1-2, 7-9, 11-12, 16-17. As detailed in the following rejections, the generic claim encompassing the elected species was not found patentable. Therefore, the provisional election of species is given effect, the examination is restricted to the elected species only, and claims not reading on the elected species are held withdrawn. MPEP 803.02; Ex parte Ohsaka, 2 USPQ2d 1460, 1461 (Bd. Pat. App. lnt. 1987). Accordingly, claims 3-6, 10, 13-15 are hereby withdrawn. Should applicant, in response to this rejection of the Markush-type claim, overcome the rejection through amendment, the amended Markush-type claim will be reexamined to the extent necessary to determine patentability of the Markush-type claim. See MPEP 803.02. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2, 7-9, 11, 16-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Abulwerdi et al. (J. Med. Chem. 2016, 59, p. 11148−11160). Abulwerdi teaches compound 7 (p. 11149): PNG media_image3.png 315 524 media_image3.png Greyscale corresponding to claim 1 formula I: PNG media_image2.png 169 384 media_image2.png Greyscale when: V1 is N; V2 is CH; W is C; X is S; R1 is CH3; R2 is H; R3 is 4-trifluoromethylphenyl. Response to Remarks - 35 USC § 102 Applicant amended the claims to include a proviso New Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1-2, 7-9, 11, 16-17 are rejected under 35 U.S.C. 112(a) as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor at the time the application was filed, had possession of the claimed invention. Applicant amended the claim 1 to add the following new proviso species: PNG media_image4.png 150 361 media_image4.png Greyscale while stating support for the added claim limitation is found: PNG media_image5.png 125 795 media_image5.png Greyscale The as-filed specification paragraph 27 is as follows: p.7: PNG media_image6.png 89 802 media_image6.png Greyscale p.8: PNG media_image7.png 120 800 media_image7.png Greyscale which does not support the new claim language. The specification does not specifically describe the added species. In addition, based on the original disclosure one of skill in the art would not recognize that Applicant possessed such a scope. As per MPEP 2163 II A: With respect to newly added or amended claims, applicant should show support in the original disclosure for the new or amended claims. See, e.g., Hyatt v. Dudas, 492 F.3d 1365, 1370, n.4 (Fed. Cir. 2007) (citing MPEP § 2163.04 which provides that a "simple statement such as ‘applicant has not pointed out where the new (or amended) claim is supported, nor does there appear to be a written description of the claim limitation ‘___’ in the application as filed’ may be sufficient where the claim is a new or amended claim, the support for the limitation is not apparent, and applicant has not pointed out where the limitation is supported."); see also MPEP §§ 714.02 and 2163.06 ("Applicant should ... specifically point out the support for any amendments made to the disclosure."); and MPEP § 2163.04 ("If applicant amends the claims and points out where and/or how the originally filed disclosure supports the amendment(s), and the examiner finds that the disclosure does not reasonably convey that the inventor had possession of the subject matter of the amendment at the time of the filing of the application, the examiner has the initial burden of presenting evidence or reasoning to explain why persons skilled in the art would not recognize in the disclosure a description of the invention defined by the claims."). The inquiry into whether the description requirement is met is a question of fact that must be determined on a case-by-case basis. AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1297, 111 USPQ2d 1780, 1788 (Fed. Cir. 2014) ("Whether a patent claim is supported by an adequate written description is a question of fact."); In re Smith, 458 F.2d 1389, 1395, 173 USPQ 679, 683 (CCPA 1972) ("Precisely how close [to the claimed invention] the description must come to comply with Sec. 112 must be left to case-by-case development."); In re Wertheim, 541 F.2d at 262, 191 USPQ at 96 (inquiry is primarily factual and depends on the nature of the invention and the amount of knowledge imparted to those skilled in the art by the disclosure). The examiner could not locate support for the new limitation, nor does there appear to be a written description of the limitation in the application as filed. See Hyatt v. Dudas, 492 F.3d 1365, 1370, 83 USPQ2d 1373, 1376 (Fed. Cir. 2007) (holding that "[MPEP] § 2163.04 (I)(B) as written is a lawful formulation of the prima facie standard for a lack of written description rejection."). There is no literal support for the added limitation and one of skill in the art would not recognize that Applicant possessed the claim scope. Thus, claim 1 and those that depend therefrom are rejected. Claim Objections Claim 12 is objected to for being dependent on a rejected base claim. Conclusion No claims allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT H HAVLIN whose telephone number is (571)272-9066. The examiner can normally be reached 9am - 6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at (571) 270-5293. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ROBERT H HAVLIN/Primary Patent Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

May 19, 2023
Application Filed
Feb 09, 2026
Non-Final Rejection mailed — §102, §112
May 08, 2026
Response Filed
Jun 03, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12649717
CYANINE-DERIVED COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
3y 5m to grant Granted Jun 09, 2026
Patent 12648928
INTERVENTION STRATEGY FOR PREVENTION OR TREATMENT OF DIABETES MELLITUS, AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE OR CARDIOVASCULAR DISEASE
3y 9m to grant Granted Jun 09, 2026
Patent 12637443
CYCLIC AMINE DERIVATIVES HAVING SEROTONIN RECEPTOR BINDING ACTIVITY
2y 11m to grant Granted May 26, 2026
Patent 12630537
PYRIDAZINONE AND METHODS OF USE THEREOF
3y 0m to grant Granted May 19, 2026
Patent 12617771
DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 10m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
52%
Grant Probability
80%
With Interview (+27.7%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1033 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month